Artesunate regulates malignant progression of breast cancer cells via lncRNA TUG1/miR-145-5p/HOXA5 axis
These findings indicate that artesunate may inhibit breast cancer progression through the lncRNA TUG1/miR-145-5p/HOXA5 axis, highlighting its potential as a promising therapeutic candidate for future clinical trials in cancer therapy.
Authors
- Ziteng Zhang
- Kaiye Du
- Ling Gai (ORCID: https://orcid.org/0000-0001-7848-4648)
- Geng Zhang (ORCID: https://orcid.org/0000-0001-9038-4316)
- Yunjiang Liu (ORCID: https://orcid.org/0000-0002-7654-873X)
- Chao Gao (ORCID: https://orcid.org/0000-0002-3470-1775)
- Yanshou Zhang
- Chao Yang (ORCID: https://orcid.org/0009-0001-4009-9573)
Institutions
- Hebei Medical University (CN)
- Fourth Hospital of Hebei Medical University (CN)
Publication Details
- Journal
- PLoS ONE
- Published
- 2025-08-04
- DOI
- https://doi.org/10.1371/journal.pone.0329490
- Citations
- 1
- Primary Topic
- Cancer-related molecular mechanisms research
- Type
- article
- Field-Weighted Citation Impact
- 0.94